Addiction
11 videos · last 6 months shuffled daily, then older videos newest first
▶
49:31 How THC Alters Brain Networks
Jodi M. Gilman, PhD, of Harvard Medical School and Massachusetts General Hospital presents a double-blind randomized crossover study of 128 regular cannabis users on how THC alters brain networks, at the Center for Medicinal Cannabis Research.
▶
56:13 First-in-Human MEAI Trial: Yale & Johns Hopkins Researchers Discuss CMND-100
Investigators from Yale and Johns Hopkins, with Clearmind CEO Adi Zuloff-Shani, discuss the first-in-human trial of CMND-100, an MEAI-based compound for alcohol use disorder.
▶
10:37 The Evidence Suggesting GLP-1s Can Curb Drug and Alcohol Cravings
PBS NewsHour's William Brangham reports on researchers testing whether GLP-1 drugs can curb people's cravings for drugs and alcohol.
▶
5:28 Drug Self-Intoxication Mortality
Aimen Shafiq, MD, of the University of Mississippi Medical Center on self-injury mortality among people with mental and behavioural disorders, which rose steadily from 1999 to 2023.
▶
33:43 Psychedelic Therapy Trials: Evidence and Methods
Psychiatrist and researcher Sandeep Nayak discusses psychedelic clinical trials, the methodological problems in the field, the FDA decision on MDMA and which research questions matter most, in an OPEN Foundation interview at ICPR.
▶
4:08 Johns Hopkins Medicine Studies Magic Mushrooms to Stop Smoking
A woman participated in a clinical trial at Johns Hopkins University to quit smoking using magic mushrooms, also known as psilocybin, and she stopped her 40-year smoking habit after taking psilocybin.
▶
1:24 A Look at a Virtual Clinical Trial for Opioid Addiction
A video shows a clinical trial site, Hometown Health Center in Dexter, Maine and focuses on a virtual clinical trial to study patients suffering from opioid addiction in rural areas.
▶
4:46 Cary Claiborne Provides Updates on FDA Path For AD04 Including New Partnership
Adial Pharmaceuticals (NASDAQ: ADIL) CEO Cary Claiborne discusses FDA alignment on Phase 3 adaptive trial design for AD04, a partnership with Genomind for at-home cheek swab testing, and a provisional patent filing extending exclusivity to 2045.
▶
3:38 What FDA and NIDA Alignment Could Mean for AUD Development
Adial Pharmaceuticals CEO Cary Claiborne on a congressional directive for FDA and NIDA to align on alcohol use disorder trial endpoints beyond abstinence, such as reduced cravings and severity.
▶
4:48 Tony Goodman Discusses AD04 Strategy and Investor Outlook
Adial Pharmaceuticals COO Tony Goodman updates on AD04 for alcohol use disorder, including a recent FDA meeting and Phase 3 trial design work with Cytel.
▶
2:16 Fast Tracking a Game Changer in Addiction
A UW psychiatric researcher Marco Pravetoni, PhD discusses clinical trials and research involving a vaccine to treat all kinds of addiction.